January 15, 2019

Jan Lundberg Joins TB Alliance Board of Directors

Lundberg has more than 20 years of experience in global R&D management, including the approval of 20+ new medicines
December 11, 2018

Schrödinger and TB Alliance Announce Collaboration to Accelerate Tuberculosis Drug Discovery

Partnership merges Schrödinger’s advanced modeling capabilities with TB Alliance’s expertise in tuberculosis biology to accelerate the development of next-generation treatments
December 4, 2018

Global TB Research Funding Continues to Fall Short

Statement on TAG Report on TB Research Funding Trends
November 28, 2018

TB Alliance Receives GHTC Partnership Award for Development of Child-Friendly TB Medicines

Fixed dose combination medicines now available across 85 countries and set to reach first 800,000 children
November 26, 2018

Closing the TB Funding Gap

November 19, 2018

TB Alliance Statement on EMA Approval of Fexinidazole

Regulatory approval of all-oral sleeping sickness medication is a global health breakthrough
October 24, 2018

TB Alliance Joins Innovative Medicines Initiative to Accelerate Development of New TB Cures

European Public-Private Partnership Enables Research to Combat Health Threats, including Drug-Resistant Tuberculosis
September 26, 2018

Statement on UN High-Level Meeting on TB

The world is listening and expecting true commitment and change
September 19, 2018

TB Alliance and Liverpool School of Tropical Medicine Collaborate to Develop New TB Therapies

New partnership supported by Medical Research Council to research drug regimens to fight drug-resistant tuberculosis
September 18, 2018

Once Again, New TB Numbers Underscore the Need for New Treatments

Statement from TB Alliance on WHO Global TB Report 2018

Pages